Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
NCT06651021Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balcinrenone in chronic kidney disease (CKD) and heart failure (HF), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity, Area under the plasma concentration-time curve from zero to time of last quantifiable concentration and 8 more. Started Oct 2024; status: completed.
02
Drugs
balcinrenone
03
Conditions
chronic kidney disease (CKD)heart failure (HF)
Beyond the preview
Go deeper on NCT06651021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651021.